Snowdon, Inc. · Monmouth Junction, New Jersey
Small-molecule therapeutics for pain, the nervous system and infection.
Snowdon is a biopharmaceutical company using its E-Prospector discovery platform to find and develop novel small-molecule drugs in three therapeutic areas with substantial unmet need.
Company overview
Three areas, one discovery engine
Snowdon Inc. is a pharmaceutical company that is focused on three major therapeutic areas with substantial market potential: acute and chronic pain, neurological disorders, and infectious diseases. These medical conditions cause immense suffering, economic hardship, and loss of life among millions of people every day. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicines.
Snowdon’s pipeline extends from NCEs to repurposing off-patent drugs for new clinical indications. The company’s preclinical lead compound, SND-121, has shown exceptional safety and efficacy when administered orally in rodent models as a treatment for neuropathic pain. SND-121 appears to treat pain through a unique mechanism of action, distinct from traditional analgesics such as opioid narcotics, NSAIDs, or the antiepileptics gabapentin and pregabalin.
In brief
- Founded2007
- FounderWilliam J. Welsh, PhD
- BasedMonmouth Junction, NJ
- Lead programSND-121
- DoD contractup to $8.2M
Therapeutic areas
Where the science is pointed
Pain
Acute and chronic pain, including neuropathic pain from shingles, diabetes, fibromyalgia and multiple sclerosis.
Neurological disorders
Glutamate excitotoxicity as a common mechanism of neuronal death, and Fragile X Syndrome as an early discovery target.
Infectious diseases
Tuberculosis and toxoplasmosis programs, and work on biowarfare pathogens under a DTRA contract.
The platform
E-Prospector
An integrated array of computational tools, an in silico library of more than five million vendor-available compounds, and filters that decide what is worth synthesising — docking and scoring, Lipinski rules, ADME/Tox, cardiotoxicity, brain permeability and efflux alerts.
Funding
Grants, venture capital and a DoD contract
Snowdon was established through an equity investment by Foundation Venture Capital Group LLC together with grants from the New Jersey Commission on Science & Technology and the National Institutes of Health.
In 2010 it was awarded a three-year contract from the DoD Transformational Medical Technologies program, worth up to $8.2 million, to develop treatments against biowarfare pathogens.
Working with Snowdon
Partnering, licensing and scientific enquiries
The company published one inbox for enquiries and one for employment. Both are reproduced as they stood.